

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763

Status	RECRUITING
Phase	Phase 2
Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment	75 participants

Key Eligibility Criteria

Inclusion (3)

- Age 18-75 years, regardless of gender;
- Weight ≥ 40.0 kg at screening;
- Diagnosed as primary membranous nephropathy through kidney biopsy.

Exclusion (5)

- Secondary membranous nephropathy.
- Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.
- Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.
- Subjects who have a malignant tumor or a history of malignant tumor
- Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.

Locations (1 total)

General hospital of eastern theater command, Nanjing, Jiangsu, China